Gastrointestinal (GI) – Metro Minnesota Community Oncology Research Consortium

Find Clinical Trials

← Back

December 15, 2025 in Gastrointestinal (GI)

GI011: A Phase III Randomized Trial of Dose Escalated Radiation in Locally Advanced Pancreas Cancer (LAPC) Patients (LAP100) (NCT06958328)

December 8, 2025 in Gastrointestinal (GI)

HARMONi-GI3

A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer

July 14, 2025 in Gastrointestinal (GI)

LUCERNA 8951-CL-0305

A Phase 3, Double-blind, Randomized Study of Zolbetuximab in Combination with Pembrolizumab and Chemotherapy (CAPOX or mFOLFOX6) in First-line Treatment of Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction…

February 19, 2025 in Gastrointestinal (GI)

S2104: Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors

October 9, 2024 in Gastrointestinal (GI)

S2303

Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE) (NCT 06203600)

May 31, 2023 in Gastrointestinal (GI)

A022101

A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASUR)

April 24, 2023 in Gastrointestinal (GI)

A022102

A022102: A Randomized Phase III Trial of mFOLFIRINOX +/- Nivolumab vs. FOLFOX +/- Nivolumab for First-line Treatment of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma

February 14, 2023 in Gastrointestinal (GI)

EA2192: APOLLO

A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

October 14, 2022 in Gastrointestinal (GI)

SGNTUC-029

An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with…

July 11, 2022 in Gastrointestinal (GI)

WF1806

WF-1806: Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults with Colorectal Cancer: The M and M Study (NCT03998202)

July 11, 2022 in Gastrointestinal (GI)

S1922

S1922: Randomized Phase II Selection Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma

June 30, 2022 in Gastrointestinal (GI)

GI008

GI008: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US) (NCT 05174169)